More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback